프로키드니 (PROK) 주가

프로키드니(PROK)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.91 (+6.11%), 시가총액 $0.49B, 52주 최저~최고 $0.56 ~ $5.18.

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartere

핵심 지표

• 현재가: $1.91 (+6.11%)
• 시가총액: $0.49B
• 52주 최저~최고: $0.56 ~ $5.18
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

프로키드니의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

프로키드니 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.1429

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 97.15
• 순이익률: 0.00%
• 영업이익률: -198.82%

자주 묻는 질문